Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals
J Nucl Med
.
2018 Jun;59(6):865-867.
doi: 10.2967/jnumed.117.204446.
Epub 2018 Mar 30.
Authors
Sally W Schwarz
1
,
Bonnie Clarke
2
Affiliations
1
Department of Radiology, Washington University School of Medicine, St. Louis, Missouri; and schwarzs@wustl.edu.
2
Research and Discovery Department, Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
PMID:
29602818
DOI:
10.2967/jnumed.117.204446
No abstract available
Publication types
Comment
MeSH terms
Drug Approval*
Radiopharmaceuticals*
United States Food and Drug Administration
Substances
Radiopharmaceuticals